Related Experiment Video

Updated: Mar 8, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K

HER2/neu as target in gastric adenocarcinoma

Bulent Cetin1, Ahmet Ozet2

  • 1Department of Internal Medicine, Division of Medical Oncology, Recep Tayyip Erdogan University Faculty of Medicine, Rize 53100, Turkey.

Translational Gastroenterology and Hepatology
|February 1, 2017
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.6K
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

803

Related Experiment Videos

Last Updated: Mar 8, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.6K
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

803

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

8.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K

Articles linked to this work by shared authors, journal, and citation graph.

Topical Diclofenac for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Prospective Real-World Study.

JCO global oncology·2026

First-Line Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data from Turkey.

Journal of clinical medicine·2026

A pragmatic adaptation of the RANO clinical risk score for IDH-Wildtype glioblastoma in the absence of MGMT promoter methylation testing.

Future oncology (London, England)·2026

Side Effect Management of Immune-related Hepatotoxicity Due to Immune Checkpoint Inhibitors: A Multicenter Study by the Turkish Oncology Group (TOG).

Journal of immunotherapy (Hagerstown, Md. : 1997)·2026

Post-Harvest UV-C Treatment of Microgreens for Inactivation of Salmonella enterica, Escherichia coli O157:H7 and Listeria monocytogenes.

Foods (Basel, Switzerland)·2026

Quinone reductase 2 reads H3 serotonylation to support neuronal maturation.

bioRxiv : the preprint server for biology·2026

Efficacy and safety of endoscopic transcecal appendectomy: a systematic review and meta-analysis.

Translational gastroenterology and hepatology·2026

Assessing variability in predictors of adequate follow-up after esophageal food bolus impaction: a retrospective study and literature review.

Translational gastroenterology and hepatology·2026

Optimizing detection and resection of colorectal polyps.

Translational gastroenterology and hepatology·2026

Dynamic feedback between IL-6 and TWIST1 drives pancreatic cancer progression.

Translational gastroenterology and hepatology·2026

Noninvasive multimodal management of portal hypertension: from early screening to precision clinical decision-making.

Translational gastroenterology and hepatology·2026

Secondary sclerosing cholangitis: contemporary etiologies, diagnostic pathways, and treatment strategies for clinicians: a narrative review.

Translational gastroenterology and hepatology·2026

Silencing GJB2 attenuates IL-1β-induced chondrocyte injury by activating Nrf2/HO-1 signaling and preserving mitochondrial function.

Folia histochemica et cytobiologica·2026

DPM2 promotes melanoma progression and serves as a prognostic factor.

Melanoma research·2026

Efficacy of combined atorvastatin and paromomycin in treating experimental cryptosporidiosis in immunosuppressed mice.

QJM : monthly journal of the Association of Physicians·2026

Pan-RAS Inhibitor Shows Activity in Advanced Lung Cancer.

Cancer discovery·2026

Purine nucleoside phosphorylase in breast cancer from metabolic regulation to targeted therapy: challenges and opportunities.

RSC medicinal chemistry·2026

Yifeixiaoji decoction as an adjunct to osimertinib therapy in advanced EGFR-mutated NSCLC: protocol for a randomized, double-blind, placebo-controlled trial.

Frontiers in medicine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us